MA55752A - Nouveaux composés et compositions pharmaceutiques associées pour le traitement de néphropathies - Google Patents
Nouveaux composés et compositions pharmaceutiques associées pour le traitement de néphropathiesInfo
- Publication number
- MA55752A MA55752A MA055752A MA55752A MA55752A MA 55752 A MA55752 A MA 55752A MA 055752 A MA055752 A MA 055752A MA 55752 A MA55752 A MA 55752A MA 55752 A MA55752 A MA 55752A
- Authority
- MA
- Morocco
- Prior art keywords
- nephropathies
- treatment
- pharmaceutical compositions
- new compounds
- associated pharmaceutical
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 208000017169 kidney disease Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1905711.6A GB201905711D0 (en) | 2019-04-24 | 2019-04-24 | Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA55752A true MA55752A (fr) | 2022-03-02 |
Family
ID=66810218
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA055752A MA55752A (fr) | 2019-04-24 | 2020-04-21 | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de néphropathies |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US12383544B2 (fr) |
| EP (1) | EP3958863B1 (fr) |
| JP (1) | JP7543304B2 (fr) |
| KR (1) | KR20220004111A (fr) |
| CN (1) | CN113727711A (fr) |
| AU (1) | AU2020263869A1 (fr) |
| BR (1) | BR112021021117A2 (fr) |
| CA (1) | CA3137445A1 (fr) |
| ES (1) | ES2982398T3 (fr) |
| GB (1) | GB201905711D0 (fr) |
| IL (1) | IL287392A (fr) |
| MA (1) | MA55752A (fr) |
| MX (1) | MX2021012544A (fr) |
| PH (1) | PH12021552680A1 (fr) |
| SG (1) | SG11202111739VA (fr) |
| WO (1) | WO2020216740A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025096453A1 (fr) * | 2023-10-30 | 2025-05-08 | Vertex Pharmaceuticals Incorporated | Composés pour le traitement d'une maladie rénale |
| WO2025121320A1 (fr) * | 2023-12-04 | 2025-06-12 | 国立大学法人山口大学 | Agent prophylactique ou thérapeutique contre la polykystose rénale |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7514463B2 (en) * | 2004-08-20 | 2009-04-07 | University Of Kansas | Lonidamine analogues and their use in male contraception and cancer treatment |
| US8362031B2 (en) | 2004-08-20 | 2013-01-29 | University Of Kansas | Lonidamine analogues and treatment of polycystic kidney disease |
| CA2769847C (fr) * | 2009-08-10 | 2019-01-08 | The Regents Of The University Of California | Inhibiteurs pyrimido-pyrrolo-quinoxaline dione de la proteine regulatrice de la conductance transmembranaire impliquee dans la fibrose kystique et leurs utilisations |
| TWI704919B (zh) * | 2012-05-31 | 2020-09-21 | 日商大塚製藥股份有限公司 | 用於預防及/或治療多囊性腎臟病之藥物 |
| US10174012B2 (en) | 2014-11-04 | 2019-01-08 | The University Of Kansas | LKB1-AMPK activators for therapeutic use in polycystic kidney disease |
| MX2018004364A (es) | 2015-10-09 | 2018-08-16 | Abbvie Sarl | Acidos pirazolo [3,4-b] piridin-6-carboxilicos sustituidos y su uso. |
| TWI720032B (zh) * | 2015-10-09 | 2021-03-01 | 比利時商葛萊伯格有限公司 | Ｎ－磺醯化吡唑并﹝３，４－ｂ﹞吡啶－６－甲醯胺及其使用方法 |
| AU2016333907A1 (en) | 2015-10-09 | 2018-04-12 | AbbVie S.à.r.l. | Novel compounds for treatment of cystic fibrosis |
| US20200289482A1 (en) * | 2017-06-21 | 2020-09-17 | The Johns Hopkins University | Cystic fibrosis transmembrane conductance regulator modulators for treating autosomal dominant polycystic kidney disease |
-
2019
- 2019-04-24 GB GBGB1905711.6A patent/GB201905711D0/en not_active Ceased
-
2020
- 2020-04-21 KR KR1020217038004A patent/KR20220004111A/ko not_active Withdrawn
- 2020-04-21 MX MX2021012544A patent/MX2021012544A/es unknown
- 2020-04-21 SG SG11202111739VA patent/SG11202111739VA/en unknown
- 2020-04-21 BR BR112021021117A patent/BR112021021117A2/pt not_active Application Discontinuation
- 2020-04-21 MA MA055752A patent/MA55752A/fr unknown
- 2020-04-21 EP EP20721493.3A patent/EP3958863B1/fr active Active
- 2020-04-21 PH PH1/2021/552680A patent/PH12021552680A1/en unknown
- 2020-04-21 JP JP2021562854A patent/JP7543304B2/ja active Active
- 2020-04-21 CA CA3137445A patent/CA3137445A1/fr active Pending
- 2020-04-21 ES ES20721493T patent/ES2982398T3/es active Active
- 2020-04-21 CN CN202080030725.9A patent/CN113727711A/zh active Pending
- 2020-04-21 US US17/605,623 patent/US12383544B2/en active Active
- 2020-04-21 WO PCT/EP2020/061083 patent/WO2020216740A1/fr not_active Ceased
- 2020-04-21 AU AU2020263869A patent/AU2020263869A1/en not_active Abandoned
-
2021
- 2021-10-19 IL IL287392A patent/IL287392A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220004111A (ko) | 2022-01-11 |
| IL287392A (en) | 2021-12-01 |
| CA3137445A1 (fr) | 2020-10-29 |
| GB201905711D0 (en) | 2019-06-05 |
| PH12021552680A1 (en) | 2022-07-04 |
| ES2982398T3 (es) | 2024-10-16 |
| BR112021021117A2 (pt) | 2021-12-14 |
| EP3958863B1 (fr) | 2024-07-03 |
| JP2022529814A (ja) | 2022-06-24 |
| US12383544B2 (en) | 2025-08-12 |
| EP3958863A1 (fr) | 2022-03-02 |
| MX2021012544A (es) | 2021-11-12 |
| EP3958863C0 (fr) | 2024-07-03 |
| JP7543304B2 (ja) | 2024-09-02 |
| SG11202111739VA (en) | 2021-11-29 |
| CN113727711A (zh) | 2021-11-30 |
| AU2020263869A1 (en) | 2021-12-23 |
| WO2020216740A1 (fr) | 2020-10-29 |
| US20220202802A1 (en) | 2022-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51200A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
| MA56019A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
| MA52873A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
| MA51739A (fr) | Compositions pharmaceutiques pour le traitement de la fibrose kystique | |
| MA50391A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de troubles inflammatoires | |
| EP3924481A4 (fr) | Compositions et méthodes de traitement d'hémoglobinopathies | |
| MA52118A (fr) | Nouveaux composés et compositions pharmaceutiques de ceux-ci destinés au traitement de la fibrose | |
| EP3704108A4 (fr) | Composés et compositions pour le traitement de troubles hématologiques | |
| MA55497A (fr) | Nouveaux composés et compositions pharmaceutiques de ceux-ci pour le traitement de troubles inflammatoires | |
| EP3890747A4 (fr) | Compositions pour le traitement de la fibrose et de l'inflammation | |
| LU92577B1 (fr) | Nouveaux composés et compositions pharmaceutiques de ceux-ci pour le traitement de la mucoviscidose | |
| EP3402533A4 (fr) | Méthodes et compositions pour le traitement d'une maladie neurologique | |
| EP3528852A4 (fr) | Méthodes et compositions pour le traitement de la maladie de fabry | |
| MA52631A (fr) | Compositions et méthodes pour le traitement de la maladie de parkinson | |
| EP3946357A4 (fr) | Formulations topiques pour le traitement de neuropathies périphériques | |
| EP3328864A4 (fr) | Composés et compositions thérapeutiques pour le traitement de troubles sociaux et de troubles liés à la toxicomanie | |
| EP3841086A4 (fr) | Composés pharmaceutiques pour le traitement de troubles médicaux du facteur d du complément | |
| EP3661553A4 (fr) | Méthodes et compositions pour le traitement des maladies à dépôts amyloïdes | |
| EP3762505A4 (fr) | Compositions et méthodes pour le traitement de la maladie de parkinson | |
| MA51056A (fr) | Compositions et méthodes pour le traitement d'affections métaboliques | |
| MA50905A (fr) | Composés et compositions pharmaceutiques de ceux-ci destinés à être utilisés dans le traitement de maladies fibrotiques | |
| MA55218A (fr) | Eskétamine pour le traitement de la dépression | |
| MA55093A (fr) | Méthodes et compositions pour le traitement du cancer | |
| EP3801478A4 (fr) | Méthodes et compositions pour la prévention ou le traitement de la calciphylaxie | |
| MA55982A (fr) | Composition pharmaceutique pour le traitement de tumeurs |